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Volume 55, Number 3 Letters to the Editor 891exclude “silent” strokes, a predictor of future cognitive deteriora-
tion.
In conclusion, based on the analysis of nearly 1500 CEAs, our
study demonstrates that preoperative treatment with clopidogrel,
particularly when it is continued to the day before surgery, seems to
be associated with a higher risk of neck bleeding after CEA,
requiring re-exploration in most cases.1 Larger studies are war-
ranted to confirm our findings and prevent this feared surgical
complication.
Claudio Baracchini, MD
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Regarding “Impact of cilostazol after endovascular
treatment for infrainguinal disease in patients with
critical limb ischemia”
We were delighted to read the recent publication of the work
by Soga et al1 regarding the use of cilostazol in patients with critical
limb ischemia (CLI). To our knowledge, this is the first and
extremely valuable multicenter, retrospective analysis study that
investigates the effects of cilostazol in this cohort of patients.
In our own practice at Barts and The London NHS Trust in
the United Kingdom, we have not used cilostazol to treat patients
with CLI. In England, cilostazol is currently only licensed for use
in patients with claudication but not CLI.2 In Scotland, however,
its use is not licensed at all!
Recently, the National Institute for Health and Clinical Ex-
cellence (NICE), an independent organization responsible for
providing national guidance on promoting good health and pre-
venting and treating ill health in England, decided not to recom-
mend the use of cilostazol for treatment of peripheral vascular
disease for any indication.3 This decision is based on a cost- and
clinical-benefit analysis of National Health Service (NHS) re-
sources. With this higher authority not recommending the use of
cilostazol in patients with claudication and no CLI, in addition to
the current worldwide financial situation, do the authors think the
use of cilostazol in patients with CLI is cost-effective? We noticed
that there is no cost analysis in their study. Did they find a financial
advantage for the use of cilostazol?
This information regarding costing is vital for rationalization
for us to implement the use of cilostazol in this cohort of patients
into our current practice in the United Kingdom. Thiva Dindyal, BSc, MBBS, MRCS (Edin), MRCS (Eng)
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We conducted a multicenter retrospective study to evaluate
he economic effectiveness of cilostazol (the purchase price of 200
g cilostazol in the United States is $4.0-$5.2 US dollars) in
atients with critical limb ischemia (CLI), with the understanding
hat this study had many limitations. The efficacy of cilostazol was
etrospectively evaluated in 618 patients who had developed CLI
or the first time.1 No significant difference in overall survival was
ound, but major amputation was significantly decreased in the
ilostazol-treated group. To evaluate the economic effectiveness of
ilostazol, it was assumed that administration of cilostazol did not
hange the mortality and provided a 50% risk reduction in the rate
f major amputation of 20% in 5 years. If 500 of 1000 patients with
LI treated with endovascular therapy are treated with aspirin and
ilostazol and the other 500 with aspirin alone, major amputation
ill be required in 100 patients in the aspirin group and 50 in the
spirincilostazol group over 5 years; therefore, the number
eeded to treat value is 10 (50 of 500). The drug price of cilostazol
t 200 mg per person is 379 yen/day ($4.7 US dollars/day; $1 
80), 138,335 yen/year ($1729 US dollars/year), and 691,675
en/5 years ($8646 US dollars/5 years). Assuming no deaths, it
akes 350 million yen ($4.3 million US dollars) to treat 500
atients with cilostazol for 5 years. Therefore, it is estimated that it
akes approximately 7 million yen ($90,000 US dollars) to prevent
ajor amputation in a patient with CLI. However, the mortality is
ctually around 11% per year, which gives an estimate of 4 to 5
illion yen (%50,000-$62,500 US dollars) to prevent major am-
utation in a patient with CLI. The mean total hospitalization cost
as 3.41 million yen ($43,000 US dollars) and the additional
ospitalization cost due to major amputation was 730,000 yen
$9100 US dollars) in 40 patients who were randomly extracted
rom this study. In patients who did not undergo major amputa-
ion, a hospitalization cost of 390,000 yen ($4900 US dollars) was
dded due to minor amputation and wound treatment. The hos-
italization cost in patients with major amputation was 340,000
en ($4250 US dollars) higher ( cost) than that in patients
ithout major amputation. Although the costs were not the same
n all patients, these results suggest that cilostazol decreased the
ospitalization cost when administered to patients with CLI. The
ealth care costs at other hospitals and the expense of hospital visits
ere not included and these costs should also be considered.The costs estimated in this study are only an approximation.
he economic validity of administration of cilostazol to patients
